ArticleThe pharmacogenomics journal2020
Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study.
Article in The pharmacogenomics journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- GWAS of CRP response to statins further supports the role of APOE in statin response: A GIST consortium study.Pharmacological research · 2025Pooled it
- Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization.medRxiv : the preprint server for health sciences · 2025Article
- The Diabetogenic Effect of Statin Use May Interact With Polygenic Risk Scores for Type 2 Diabetes: Evidence From the UK Biobank.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025Article
- Disentangling the consequences of type 2 diabetes on targeted metabolite profiles using causal inference and interaction QTL analyses.PLoS genetics · 2024Article
- Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.British journal of clinical pharmacology · 2023Article
- Mendelian Randomization Analysis Reveals Statins Potentially Increase Amyotrophic Lateral Sclerosis Risk Independent of Peripheral Cholesterol-Lowering Effects.Biomedicines · 2023Article
- Article
- Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer.Frontiers in pharmacology · 2023Article
- Statins and risk of type 2 diabetes: mechanism and clinical implications.Frontiers in endocrinology · 2023Review
- Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk.Brain : a journal of neurology · 2022Article
- A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy.Clinics and practice · 2022Article
- Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management.EBioMedicine · 2022Article
- Coconut products alleviate hyperglycaemic, hyperlipidimic and nephropathy indices in streptozotocin-induced diabetic wistar rats.Saudi journal of biological sciences · 2021Article
- Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease-a comparison in the MONICA/KORA study.Cardiovascular diabetology · 2020Article
- Pleiotropic use of Statins as non-lipid-lowering drugs.International journal of biological sciences · 2020Review
- Causal Effects of Overall and Abdominal Obesity on Insulin Resistance and the Risk of Type 2 Diabetes Mellitus: A Two-Sample Mendelian Randomization Study.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 10 institutions in 4 countries.
Funding
Abstract
It remains unclear whether the increased risk of new-onset type 2 diabetes (T2D) seen in statin users is due to low LDL-C concentrations, or due to the statin-induced proportional change in LDL-C. In addition, genetic instruments have not been proposed before to examine whether liability to T2D might cause greater proportional statin-induced LDL-C lowering. Using summary-level statistics from the Genomic Investigation of Statin Therapy (GIST, n
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.